查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2010059

銀屑病治療市場：2026-2032年全球市場預測（按藥物類別、給藥途徑、銀屑病類型、患者人口統計特徵、分銷管道和治療環境分類）

Psoriasis Drugs Market by Drug Class, Route Of Administration, Psoriasis Type, Patient Type, Distribution Channel, Treatment Setting - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，乾癬治療市場價值將達到 121.8 億美元，到 2026 年將成長至 135.9 億美元，到 2032 年將達到 276.3 億美元，年複合成長率為 12.41%。

主要市場統計數據
基準年 2025 121.8億美元
預計年份：2026年 135.9億美元
預測年份 2032 276.3億美元
複合年成長率 (%) 12.41%

權威概述了當前銀屑病治療方法、制度壓力以及影響銀屑病治療發展和商業化的策略挑戰。

目前銀屑病治療的特點是科學的快速發展和商業性趨勢的不斷演變。標靶生物製藥和口服小分子化合物的進步正在拓展治療選擇，並提高了人們對療效、持續緩解和患者便利性的期望。同時，支付方的嚴格審查、日益複雜的供應鏈以及不斷變化的監管要求，都要求製藥公司和醫療機構調整其營運和商業性策略。因此，相關人員必須權衡臨床潛力與實際考量，例如生產規模化、真實世界安全性監測以及如何傳遞差異化價值。

臨床、監管和商業性方面的變革正在重新定義銀屑病治療的差異化、獲取途徑和價值主張。

科學突破、監管進步以及患者對個人化醫療的期望正在重塑銀屑病治療的模式。針對白細胞介素路徑的生物製藥和口服標靶抑制劑正在加速治療方案的差異化，引導臨床醫師考慮針對特定機制的治療方案，以惠及以往傳統治療方法難以涵蓋的患者亞群。同時，法律規範正採用更有效率的策略，基於可靠的生物標記和真實世界數據，核准和擴展新藥的適應症，使其能夠快速應用於臨床實踐。

到 2020 年代中期，不斷變化的美國關稅措施對乾癬治療的供應鏈、籌資策略和市場進入趨勢的累積影響。

美國近期對藥品原料和成品的關稅結構調整，為銀屑病治療藥物的全球供應鏈帶來了新的複雜性。活性成分、生物製藥和輔助材料的關稅變化可能會增加依賴國際採購的製造商的接收成本，促使他們重新評估供應商組合和物流策略。為此，各組織正在探索近岸外包、雙重採購和合約避險等措施，以確保原料供應穩定並保障生產的連續性。

將治療領域、給藥途徑、患者表現型、人口統計特徵、分銷管道和醫療保健環境與策略重點聯繫起來的基於全面細分的洞察。

深入了解銀屑病市場細分如何影響產品開發、臨床定位和商業性策略至關重要。治療分類將藥物分為生物製藥和小分子藥物。生物製藥包括標靶藥物，如IL-17抑制劑、IL-23抑制劑和TNF抑制劑；而小分子藥物則包括JAK抑制劑和PDE4抑制劑。每類藥物在療效、安全性、給藥途徑和生產製造方面都有其獨特的考量因素，這些因素會影響臨床醫師在選擇藥物和健保報銷方面的決策。

影響美洲、歐洲、中東和非洲以及亞太地區監管策略、准入途徑和商業化方法的區域特定趨勢。

區域趨勢持續影響美洲、歐洲、中東和非洲以及亞太地區的研發重點、監管規劃和商業策略。在美洲，成熟的法規環境和完善的專業醫療網路推動創新生物製藥和先進支援服務的快速普及，而與支付方的談判以及納入處方藥目錄仍然至關重要。在該地區，臨床醫生網路和患者權益組織往往推動著高效治療方法的早期應用，而報銷機制則要求明確證明其長期療效。

公司層面的乾癬治療策略，強調臨床差異化、生產彈性、符合支付方需求的證據產生、以病人為中心的商業化。

在乾癬治療領域，領先的製藥和生物技術公司正面臨許多複雜因素的挑戰：臨床差異化、生產要求以及支付者的參與。成熟的生物製藥研發公司正在加大對下一代白細胞介素標靶藥物和生命週期管理的投資，而較小的生物技術公司則專注於創新的作用機制和基於生物標記的適應症。同時，專業製藥公司正在推廣口服小分子藥物和聯合治療，這些藥物和療法優先考慮給藥的便利性，以滿足希望避免注射的患者亞群。儘管這些公司的情況各不相同，但它們的戰略重點都指向同一個目標：透過給藥和支持方面的創新，證明藥物的持續療效，提高安全性，並最佳化患者體驗。

為行業領導者制定可操作的策略重點，以協調臨床差異化、製造韌性、支付方參與和以患者為中心的商業化，從而實現永續的成功。

產業領導企業應採取多管齊下的策略，平衡科研投入、營運效率和支付方參與，以在不斷發展的銀屑病治療領域取得成功。優先發展那些透過清晰的作用機制實現差異化，並結合可靠的安全性和永續性終點的研發項目；設計能夠收集患者報告結果和真實世界療效數據的臨床試驗，以支持全面的價值提案。同時，應投入資源確保生產的柔軟性，包括區域生產能力和檢驗的替代供應商，以降低貿易政策變化帶來的風險，並防止臨床和商業性供應中斷。

本報告的策略和營運結論得到了詳細的調查方法支持，包括與主要專家的對話、對二手證據的檢驗驗證以及基於情境的分析。

本研究整合了對一手和二手資料的系統性回顧、專家訪談以及定性分析，以得出嚴謹而令人信服的見解。主要資訊來源包括對臨床意見領袖、支付方、供應鏈專家和商業高管的訪談，這些訪談提供了有關治療方法採納、報銷趨勢和營運限制的背景資訊。二手研究涵蓋了同行評審的臨床文獻、監管指導文件、上市公司資訊披露以及生產技術參考資料，以支持臨床機制、安全性考慮和生產實際情況。

結論強調了整合科學創新、營運韌性、與支付方一致的證據和以病人為中心的服務體系對於實現治療效果的重要性。

總之，目前銀屑病治療領域蘊藏著巨大的科研機遇，但也面臨日益複雜的營運與商業挑戰。生物製藥和標靶小分子化合物的進步提高了治療標準，但要將這些進步轉化為永續的患者獲益，需要製定一項綜合策略，整合循證醫學證據、生產韌性以及與支付方相符的價值論證。相關人員必須認知到，僅靠臨床差異化是不夠的，還需要供應鏈的靈活性來展現長期療效、以病人為中心的交付機制，以及對真實世界數據（REW）計畫的同步投資。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 銀屑病治療市場：依藥物類別分類

  • 生物製藥
    • IL-17抑制劑
    • IL-23抑制劑
    • TNF抑制劑
  • 小分子藥物
    • JAK抑制劑
    • PDE4抑制劑

第9章 銀屑病治療市場：依給藥途徑分類

  • 注射藥物
    • 靜脈
    • 皮下
  • 口服
    • 膠囊
    • 懸浮液
    • 藥片
  • 外用
    • 奶油
    • 形式
    • 凝膠
    • 軟膏

第10章：以銀屑病類型分類的乾癬治療市場

  • 紅皮病型乾癬
  • 水滴狀乾癬
  • 反向銀屑病
  • 指甲銀屑病
  • 斑塊型乾癬
  • 膿皰型乾癬
  • 頭部銀屑病

第11章：按患者群體分類的銀屑病治療市場

  • 成人
  • 老年人
  • 兒童

第12章 銀屑病治療市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 專科藥房

第13章：依治療環境分類的乾癬治療市場

  • 居家治療
  • 住院治療
  • 專業皮膚科診所

第14章 銀屑病治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 銀屑病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 銀屑病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國銀屑病治療市場

第18章：中國銀屑病治療市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Almirall SA
  • Amgen Inc
  • AstraZeneca PLC
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Dermavant Sciences Ltd.
  • Eli Lilly and Company
  • Glenmark Pharmaceuticals Ltd.
  • Incyte Corporation
  • Johnson & Johnson Services, Inc.
  • LEO Pharma A/S
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • UCB SA
Product Code: MRR-434CCDA051B5

The Psoriasis Drugs Market was valued at USD 12.18 billion in 2025 and is projected to grow to USD 13.59 billion in 2026, with a CAGR of 12.41%, reaching USD 27.63 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 12.18 billion
Estimated Year [2026] USD 13.59 billion
Forecast Year [2032] USD 27.63 billion
CAGR (%) 12.41%

An authoritative introduction summarizing the current therapeutic modalities, systemic pressures, and strategic questions shaping psoriasis drug development and commercialization

The psoriasis therapeutics landscape has entered a phase defined by rapid scientific progress and shifting commercial dynamics. Advances in targeted biologic agents and oral small molecules have expanded therapeutic options and raised expectations for improved efficacy, remission durability, and patient convenience. At the same time, payer scrutiny, supply chain complexity, and evolving regulatory expectations require manufacturers and healthcare providers to adapt operational and commercial approaches. Consequently, industry stakeholders must reconcile clinical promise with pragmatic considerations including manufacturing scalability, real-world safety monitoring, and differentiated value communication.

This introduction frames the subsequent analysis by summarizing the current therapeutic modalities, the principal clinical and commercial pressures, and the strategic questions that companies, clinicians, and payers are now confronting. It outlines how therapeutic classification, administration route, patient severity, psoriasis subtype, patient demographics, distribution channels, and treatment settings collectively shape adoption pathways and long-term care models. By situating recent innovations within realistic implementation constraints, this section prepares readers to assess strategic options, anticipate operational bottlenecks, and prioritize investments that will deliver sustained clinical and commercial returns.

Transformative clinical, regulatory, and commercial shifts are converging to redefine therapeutic differentiation, access pathways, and value demonstration in psoriasis care

The psoriasis treatment paradigm is being reshaped by converging scientific breakthroughs, regulatory evolution, and patient expectations for personalized care. Biologics targeting interleukin pathways and orally administered targeted inhibitors have accelerated therapeutic differentiation, leading clinicians to consider mechanism-specific choices for patient subgroups previously underserved by older treatments. Concurrently, regulatory pathways are accommodating more streamlined approval strategies for novel agents and for label expansions based on robust biomarker and real-world evidence, enabling faster clinical integration.

Pharmacoeconomic considerations have gained prominence, compelling manufacturers to demonstrate value through comparative effectiveness, durability, and patient-reported outcomes rather than relying solely on clinical efficacy endpoints. Distribution and delivery innovations, including increased use of specialty pharmacies, home-based administration pathways, and digital adherence supports, are altering how patients engage with treatment regimens. As a result, commercial success increasingly depends on an integrated approach that aligns clinical differentiation with robust evidence of long-term benefit, patient-centric delivery solutions, and payer-aligned value propositions. These transformative shifts are creating both opportunities and heightened competitive pressures across the therapeutic ecosystem.

Cumulative implications of evolving United States tariff measures on psoriasis drug supply chains, sourcing strategies, and commercial access dynamics through mid-decade

Recent policy developments introducing or adjusting United States tariff structures for pharmaceutical inputs and finished products have introduced new layers of complexity into global psoriasis drug supply chains. Tariff changes targeting active pharmaceutical ingredients, biologic components, and ancillary materials have the potential to increase landed costs for manufacturers that rely on international sourcing, prompting reassessments of supplier portfolios and logistics strategies. In response, organizations are evaluating nearshoring, dual-sourcing, and contractual hedges to stabilize input availability and protect production continuity.

Beyond direct cost implications, tariffs can influence the timing of product launches and the sequencing of market access activities by shifting operational priorities toward supply-chain resilience. Clinical trial supply logistics that span borders may require additional customs planning and contingency stock to maintain enrollment schedules. Meanwhile, manufacturers with vertically integrated production or domestic biologics manufacturing capabilities may find strategic advantages in cost predictability and regulatory alignment. Importantly, payers and procurement stakeholders are sensitive to any sustained pricing pressures that could affect formulary dynamics and contracting negotiations, which in turn influences manufacturer strategies for rebates, risk-sharing agreements, and patient support programs.

In summary, tariffs act as a catalyst for broader supply-chain modernization and geographic diversification of manufacturing. Stakeholders are therefore advised to adopt a holistic view that balances near-term operational responses with longer-term investments in manufacturing agility, alternative sourcing, and collaborative agreements that mitigate exposure to trade policy volatility.

Comprehensive segmentation-driven insights linking therapeutic class, administration route, patient phenotype, demographics, distribution channels, and care settings to strategic priorities

A nuanced understanding of how the psoriasis market segments informs product development, clinical positioning, and commercial engagement. Therapeutic classification differentiates between biologic therapies and small-molecule agents; biologics encompass targeted classes such as IL-17 inhibitors, IL-23 inhibitors, and TNF inhibitors, while small molecules include JAK inhibitors and PDE4 inhibitors. Each class carries distinct efficacy, safety, administration, and manufacturing considerations that influence clinician selection and reimbursement discussions.

Route of administration is a critical determinant of patient preference and health-system workflows, spanning injectable, oral, and topical modalities. Injectable formulations are further categorized by intravenous and subcutaneous delivery, each with unique clinical monitoring and administration infrastructure requirements; oral options include capsules, suspensions, and tablets that vary in dosing convenience and pharmacokinetic profiles; topical therapies are formulated as creams, foams, gels, or ointments tailored to lesion characteristics and patient adherence. Patient severity divides the landscape into mild-to-moderate and moderate-to-severe presentations, guiding escalation pathways and eligibility for systemic or biologic therapies.

Psoriasis manifests in clinically distinct subtypes including erythrodermic, guttate, inverse, nail, plaque, pustular, and scalp presentations, and these phenotypes often necessitate differentiated therapeutic strategies and outcome metrics. Patient demographics span adults, geriatric populations, and pediatric cohorts, each with unique safety and dosing considerations that affect labeling, trial design, and market positioning. Distribution channels influence access and support structures, encompassing hospital pharmacies, online pharmacies, retail outlets, and specialty pharmacies that play varying roles in reimbursement coordination and patient education. Finally, treatment settings range from home-based care to hospital-based management and specialty dermatology clinics, shaping service delivery models, adherence supports, and opportunities for remote monitoring. Collectively, these segmentation dimensions should be integrated into clinical development plans, commercial launch strategies, and payer engagement frameworks to ensure alignment with real-world treatment pathways and stakeholder needs.

Region-specific dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence regulatory strategy, access pathways, and commercialization approaches

Regional dynamics continue to shape development priorities, regulatory planning, and commercial strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, a mature regulatory environment and established specialty care networks favor rapid uptake of innovative biologics and advanced support services, alongside ongoing emphasis on payer negotiations and formulary placement. Clinician networks and patient advocacy channels in this region frequently drive early adoption patterns for high-efficacy therapies, while reimbursement mechanisms require clear demonstration of long-term benefit.

In Europe, Middle East & Africa, fragmented regulatory frameworks and diverse payer systems necessitate regionally tailored value dossiers and real-world evidence strategies to secure access. Parallel regulatory pathways and heightened health-technology assessment scrutiny often demand comparative effectiveness and cost-effectiveness evidence, prompting manufacturers to plan multi-country data generation and differentiated pricing strategies. In addition, supply-chain constraints in some markets influence distribution choices and the need for local partnership strategies.

Asia-Pacific markets display a heterogeneous mix of rapid adoption in advanced urban centers and variable access across emerging markets. Regulatory timelines and domestic manufacturing policies can influence launch sequencing, and patient populations with distinct genetic or phenotypic characteristics may require targeted clinical evidence. Across all regions, the increasing role of specialty pharmacies, digital engagement tools, and home-based treatment solutions is reshaping patient journeys and requiring manufacturers to craft region-sensitive patient support and commercial models. These regional nuances should guide prioritization of launch resources, evidence generation, and distribution partnerships.

Company-level strategies emphasizing clinical differentiation, manufacturing agility, payer-aligned evidence generation, and patient-centric commercialization in psoriasis therapeutics

Leading pharmaceutical and biotech companies active in psoriasis therapeutics are navigating a complex mix of clinical differentiation, manufacturing demands, and payer engagement. Established biologics developers are intensifying investments in next-generation interleukin-targeting agents and lifecycle management, while smaller biotechs focus on innovative mechanisms of action and biomarker-driven indications. Concurrently, specialty pharmaceutical firms are advancing oral small molecules that emphasize ease of administration and combination strategies to address patient subgroups seeking non-injectable options. Across these varied company profiles, strategic priorities coalesce around demonstrating durable efficacy, improving safety profiles, and optimizing patient experience through delivery and support innovations.

Operationally, companies are strengthening manufacturing agility and partnering with contract development and manufacturing organizations to secure biologics capacity and ensure rapid scale-up for clinical and commercial supply. Commercially, organizations are aligning evidence generation with payer expectations by investing in real-world outcomes research and longitudinal safety monitoring. Collaboration with specialty pharmacies and digital health vendors is increasingly common to support adherence, remote monitoring, and patient education. Mature players often leverage global networks to expedite regulatory filings and market entry, while emerging entrants prioritize niche differentiation, strategic partnerships, and targeted clinical programs to gain footholds in specific patient segments. The combined effect is a competitive environment where therapeutic innovation must be matched by robust supply, evidence, and patient-centric commercialization capabilities.

Actionable strategic priorities for industry leaders to align clinical differentiation, manufacturing resilience, payer engagement, and patient-centric commercialization for durable success

Industry leaders should adopt a multi-pronged strategy that balances scientific investment with pragmatic operations and payer engagement to prosper in the evolving psoriasis landscape. Prioritize development programs that pair clear mechanistic differentiation with robust safety and durability endpoints, and design clinical trials that capture patient-reported outcomes and real-world effectiveness dimensions to support comprehensive value narratives. Simultaneously, commit resources to manufacturing flexibility, including regional capacity and validated alternate suppliers, to reduce exposure to trade policy fluctuations and to support uninterrupted clinical and commercial supply.

Engage early and iteratively with payers and health-technology assessment bodies to align evidence generation with reimbursement expectations, and structure innovative contracting arrangements that share risk and demonstrate outcome linkage. Invest in distribution and patient-support ecosystems by cultivating partnerships with specialty pharmacies and digital health providers that enhance adherence, remote monitoring, and home-based administration capabilities. Finally, implement a regionalized market-entry playbook that tailors regulatory submissions, pricing strategies, and patient engagement to local system characteristics while preserving global evidence coherence. By integrating clinical excellence with operational resilience and payer-centric value demonstration, organizations can create defensible pathways to sustained adoption and meaningful patient outcomes.

Methodology detailing primary expert engagements, secondary evidence triangulation, and scenario-based analyses underpinning strategic and operational conclusions in the report

This research synthesizes a structured review of primary and secondary sources, expert consultations, and qualitative analyses to ensure rigorous and defensible findings. Primary inputs included interviews with clinical thought leaders, payers, supply-chain specialists, and commercial executives who provided context on treatment adoption, reimbursement dynamics, and operational constraints. Secondary research encompassed peer-reviewed clinical literature, regulatory guidance documents, public company disclosures, and technical manufacturing references to corroborate clinical mechanisms, safety considerations, and production realities.

Analytical methods integrated thematic synthesis of qualitative inputs, cross-validation of regulatory and clinical evidence, and scenario-based assessment of supply-chain and policy impacts. The methodology emphasized transparency in data provenance, careful triangulation of diverse information sources, and sensitivity analyses for operational risk factors. Where possible, findings were corroborated with multiple independent sources to reduce bias, and expert reviewers provided validation of clinical interpretations and strategic implications. Limitations are acknowledged; specifically, the analysis focuses on structural, clinical, and operational dynamics rather than quantitative market projections. The approach supports actionable insights for strategic planning, product development prioritization, and evidence generation strategies.

Concluding synthesis highlighting the imperative to integrate scientific innovation, operational resilience, payer-aligned evidence, and patient-centric delivery to realize therapeutic impact

In conclusion, the psoriasis therapeutics landscape offers substantial scientific opportunity coupled with heightened operational and commercial complexity. Advances in biologics and targeted small molecules have raised the standard of care, yet successful translation into sustained patient benefit requires comprehensive strategies that integrate evidence generation, manufacturing resilience, and payer-aligned value demonstration. Stakeholders must recognize that clinical differentiation alone is insufficient without parallel investments in supply-chain agility, patient-centric delivery mechanisms, and real-world evidence programs that substantiate long-term outcomes.

Moving forward, companies that proactively align clinical development with pragmatic access strategies and robust patient support models will be best positioned to navigate regulatory heterogeneity and payer demands. Moreover, organizations that adapt supply networks to mitigate policy and trade risks can secure competitive advantages in launch execution and continuity of supply. Ultimately, a holistic approach that marries scientific innovation with operational excellence and strategic collaborations will drive meaningful improvements in patient care while enabling sustainable commercial performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Psoriasis Drugs Market, by Drug Class

  • 8.1. Biologics
    • 8.1.1. IL 17 Inhibitors
    • 8.1.2. IL 23 Inhibitors
    • 8.1.3. TNF Inhibitors
  • 8.2. Small Molecules
    • 8.2.1. JAK Inhibitors
    • 8.2.2. PDE4 Inhibitors

9. Psoriasis Drugs Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intravenous
    • 9.1.2. Subcutaneous
  • 9.2. Oral
    • 9.2.1. Capsules
    • 9.2.2. Suspensions
    • 9.2.3. Tablets
  • 9.3. Topical
    • 9.3.1. Creams
    • 9.3.2. Foams
    • 9.3.3. Gels
    • 9.3.4. Ointments

10. Psoriasis Drugs Market, by Psoriasis Type

  • 10.1. Erythrodermic Psoriasis
  • 10.2. Guttate Psoriasis
  • 10.3. Inverse Psoriasis
  • 10.4. Nail Psoriasis
  • 10.5. Plaque Psoriasis
  • 10.6. Pustular Psoriasis
  • 10.7. Scalp Psoriasis

11. Psoriasis Drugs Market, by Patient Type

  • 11.1. Adults
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Psoriasis Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies
  • 12.4. Specialty Pharmacies

13. Psoriasis Drugs Market, by Treatment Setting

  • 13.1. Home-Based Treatment
  • 13.2. Hospital-Based Care
  • 13.3. Specialty Dermatology Clinics

14. Psoriasis Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Psoriasis Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Psoriasis Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Psoriasis Drugs Market

18. China Psoriasis Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Almirall S.A.
  • 19.7. Amgen Inc
  • 19.8. AstraZeneca PLC
  • 19.9. Biogen Inc.
  • 19.10. Boehringer Ingelheim International GmbH
  • 19.11. Bristol-Myers Squibb Company
  • 19.12. Dermavant Sciences Ltd.
  • 19.13. Eli Lilly and Company
  • 19.14. Glenmark Pharmaceuticals Ltd.
  • 19.15. Incyte Corporation
  • 19.16. Johnson & Johnson Services, Inc.
  • 19.17. LEO Pharma A/S
  • 19.18. Merck & Co., Inc.
  • 19.19. Novartis AG
  • 19.20. Pfizer Inc.
  • 19.21. Sanofi S.A.
  • 19.22. Sun Pharmaceutical Industries Ltd
  • 19.23. Takeda Pharmaceutical Company Limited
  • 19.24. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PSORIASIS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PSORIASIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 17 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 17 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 17 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 23 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 23 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 23 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY FOAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY FOAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY FOAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ERYTHRODERMIC PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ERYTHRODERMIC PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ERYTHRODERMIC PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GUTTATE PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GUTTATE PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GUTTATE PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INVERSE PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INVERSE PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INVERSE PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY NAIL PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY NAIL PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY NAIL PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PUSTULAR PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PUSTULAR PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PUSTULAR PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SCALP PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SCALP PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SCALP PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOME-BASED TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOME-BASED TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOME-BASED TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL-BASED CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL-BASED CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL-BASED CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY DERMATOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY DERMATOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY DERMATOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 231. GCC PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. GCC PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 233. GCC PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 234. GCC PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 235. GCC PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. GCC PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 237. GCC PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 238. GCC PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 239. GCC PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. GCC PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. GCC PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. GCC PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 267. G7 PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. G7 PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 269. G7 PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 270. G7 PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 271. G7 PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 272. G7 PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 273. G7 PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 274. G7 PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 275. G7 PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. G7 PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. G7 PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. G7 PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 279. NATO PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. NATO PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 281. NATO PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 282. NATO PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 283. NATO PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 284. NATO PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 285. NATO PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 286. NATO PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 287. NATO PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. NATO PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. NATO PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 290. NATO PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 291. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)